These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

478 related items for PubMed ID: 18569391

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview.
    Serrone L, Zeuli M, Sega FM, Cognetti F.
    J Exp Clin Cancer Res; 2000 Mar; 19(1):21-34. PubMed ID: 10840932
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. [Combination of dacarbazine, cisplatin and interferon alpha in the treatment of metastatic melanoma].
    Tessier MH, Mansat E, Legoux B, Litoux P, Dreno B.
    Ann Dermatol Venereol; 1996 Mar; 123(9):538-42. PubMed ID: 9615103
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Multicentre, open, noncomparative Phase II trial to evaluate the efficacy and tolerability of fotemustine, cisplatin, alpha-interferon and interleukin-2 in advanced melanoma patients.
    Ridolfi L, Fiorentini G, Guida M, Michiara M, Freschi A, Aitini E, Ballardini M, Bichisao E, Ridolfi R, Italian Melanoma Intergroup.
    Melanoma Res; 2009 Apr; 19(2):100-5. PubMed ID: 19262411
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Interleukin-2-based biochemotherapy for patients with stage IV melanoma: long-term survivors outside a clinical trial setting.
    Hess V, Herrmann R, Veelken H, Schwabe M.
    Oncology; 2007 Apr; 73(1-2):33-40. PubMed ID: 18332650
    [Abstract] [Full Text] [Related]

  • 35. [Long-term results of adjuvant chemotherapy after therapeutic lymph node dissection in patients with cutaneous malignant melanoma].
    Kretschmer L, Helmbold P, Emmert S, Marsch WC.
    Hautarzt; 2002 Aug; 53(8):536-41. PubMed ID: 12221468
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma.
    Atkins MB, Gollob JA, Sosman JA, McDermott DF, Tutin L, Sorokin P, Parker RA, Mier JW.
    Clin Cancer Res; 2002 Oct; 8(10):3075-81. PubMed ID: 12374674
    [Abstract] [Full Text] [Related]

  • 39. Subcutaneous interleukin-2 and interferon-alpha therapy associated with cisplatin monochemotherapy in the treatment of metastatic melanoma.
    Andrès P, Cupissol D, Guillot B, Avril MF, Drèno B.
    Eur J Dermatol; 1998 Jun; 8(4):235-9. PubMed ID: 9649695
    [Abstract] [Full Text] [Related]

  • 40. Biochemotherapy with carmustine, cisplatin, dacarbazine, tamoxifen and low-dose interleukin-2 for patients with metastatic malignant melanoma.
    Su PJ, Chen JS, Liaw CC, Chang HK, Wang HM, Yang TS, Lin YC, Liau CT, Yang HY, Yeh KY, Ho MM, Chang NJ, Wang CH, Chang JW.
    Chang Gung Med J; 2011 Jun; 34(5):478-86. PubMed ID: 22035892
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 24.